Bcr-Abl inhibitor DCC-2036, Purity ≥98%

Synonym: 1020172-07-9; Bcr-Abl inhibitor; DCC2036

MDL: MFCD19443646
CAS Number: 1020172-07-9
Compound CID: 25066467

Product Size

5 mg; 10 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

DCC-2036, soluble in DMSO and ethanol and insoluble in water, specifically inhibits the activity of the Bcr-Abl tyrosine kinase. It targets Abl1 (H396P), p-Abl1 (native), AuroraA, c-Kit, CDK2/CyclinD, FGR, FLT3, HCK, KDR, Lyn, and p-Abl1(T315I).

Molecular Weight

553.59

Molecular Formula

C₃₀H₂₈FN₇O₃

Targets

Abl1 (H396P): 1.4 nM; p-Abl1 (native): 2 nM; AuroraA: >5 μM; c-Kit: 481 nM; CDK2/CyclinD: >5 μM; FGR: 38 nM; FLT3: 2 nM; HCK: 40 nM; KDR: 4 nM; Lyn: 29 nM; p-Abl1 (T315I): 4 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 103 mg/mL (186.05 mM); Water: Insoluble; Ethanol: 15 mg/mL (27.09 mM)

Identity

Confirmed by NMR/HPLC/MS.

Applications

DCC-2036 offers a framework for researching alternative therapies to overcome resistance in chronic myeloid leukemia.